---
title: "HWHG: Eicosapentaenoic Acid Ethyl Ester Soft Capsules Obtain Drug Registration Certificate"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/255576303.md"
description: "HWHG announced that its wholly-owned subsidiary Wuhan Puke has obtained the drug registration certificate for Eicosapentaenoic Acid Ethyl Ester Soft Capsules issued by the National Medical Products Administration. This approval qualifies the company to sell the drug in the domestic market, further enriches its product line, and is expected to have a positive impact on the company"
datetime: "2025-09-02T09:02:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/255576303.md)
  - [en](https://longbridge.com/en/news/255576303.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/255576303.md)
---

# HWHG: Eicosapentaenoic Acid Ethyl Ester Soft Capsules Obtain Drug Registration Certificate

According to the Zhitong Finance APP, HWHG (600079.SH) announced that its wholly-owned subsidiary, Renfu Puke Pharmaceutical (Wuhan) Co., Ltd. (referred to as "Wuhan Puke"), recently received the "Drug Registration Certificate" for Eicosapentaenoic Acid Ethyl Ester Soft Capsules issued by the National Medical Products Administration. The approval of Eicosapentaenoic Acid Ethyl Ester Soft Capsules marks the company's qualification to sell this drug in the domestic market. This product further enriches the company's product line, and its market launch will have a positive impact on the company

### Related Stocks

- [600079.CN](https://longbridge.com/en/quote/600079.CN.md)

## Related News & Research

- [Humanwell unit Yichang Renfu wins China nod for labor pain trial of sufentanil injection](https://longbridge.com/en/news/295637927.md)
- [Unitree's 'Superman' Robot Smashes Human Record for Standing Vertical Jump](https://longbridge.com/en/news/296183985.md)
- [China's Lumos eyes fresh funding, potential listing as factory robot sales grow](https://longbridge.com/en/news/296187333.md)
- [Asta Energy Solutions lifts 2026 adjusted EBITDA forecast to EUR 60-64 million](https://longbridge.com/en/news/296229411.md)
- [CanSinoBIO's NDA for Td5cp Adolescent and Adult Accepted, Further Strengthening Its Diversified Vaccine Pipeline](https://longbridge.com/en/news/296024108.md)